BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35419462)

  • 21. Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer.
    Gao S; Du S; Lu Z; Xin J; Gao S; Sun H
    Eur Radiol; 2020 Feb; 30(2):1191-1201. PubMed ID: 31493211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Lu H; Wu Y; Liu X; Huang H; Jiang H; Zhu C; Man Y; Chen Z; Long X; Pang Q; Peng L; Li X; Gu J; Deng S; Xing L
    Oncol Res; 2022 Jan; 28(9):929-944. PubMed ID: 34544526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.
    Shim SH; Lee SW; Park JY; Kim YS; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2013 Jan; 128(1):54-59. PubMed ID: 23063760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strain elastography as an early predictor of long-term prognosis in patients with locally advanced cervical cancers treated with concurrent chemoradiotherapy.
    Xu Y; Zhu L; Zhu L; Wang H; Ru T; Liu B; He J; Tian S; Zhou Z; Yang X
    Eur Radiol; 2020 Jan; 30(1):471-481. PubMed ID: 31359126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
    Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma.
    Kgokolo MCM; Malinga NZ; Steel HC; Meyer PWA; Smit T; Anderson R; Rapoport BL
    Transl Oncol; 2024 Apr; 42():101867. PubMed ID: 38308919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups.
    Todo Y; Watari H
    Chin J Cancer Res; 2016 Apr; 28(2):221-7. PubMed ID: 27199520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI.
    Lee JE; Huh SJ; Nam H; Ju SG
    Ann Nucl Med; 2013 Jan; 27(1):37-45. PubMed ID: 23054833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histogram analysis of apparent diffusion coefficient for monitoring early response in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy.
    Meng J; Zhu L; Zhu L; Ge Y; He J; Zhou Z; Yang X
    Acta Radiol; 2017 Nov; 58(11):1400-1408. PubMed ID: 28273745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: A single-institutional retrospective study from a prospective database.
    Liu B; Li L; Wang M; Wei L; Li J; Zou W; Lv Y; Zhang H; Liu S
    Gynecol Oncol; 2019 Sep; 154(3):583-589. PubMed ID: 31307665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
    Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
    Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early treatment response of patients undergoing concurrent chemoradiotherapy for cervical cancer: An evaluation of integrated multi-parameter PET-IVIM MR.
    Xu C; Sun H; Du S; Xin J
    Eur J Radiol; 2019 Aug; 117():1-8. PubMed ID: 31307633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between IVIM parameters and treatment response in locally advanced squamous cell cervical cancer treated by chemoradiotherapy.
    Perucho JAU; Wang M; Vardhanabhuti V; Tse KY; Chan KKL; Lee EYP
    Eur Radiol; 2021 Oct; 31(10):7845-7854. PubMed ID: 33786654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant chemoradiotherapy versus pure radiotherapy in locally advanced cervical cancer: a retrospective analysis of complications and clinical outcome.
    Yang X; Wang J; Lin L; Gao D; Yin L
    Eur J Gynaecol Oncol; 2016 Aug; 37(4):499-503. PubMed ID: 29894074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 36. PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer.
    Wang C; Liu L; Li X; Lei J; Li Y; Shen Z; Shi H; Cheng Y
    Future Oncol; 2024 Jun; ():1-12. PubMed ID: 38861299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. sCD28, sCD80, sCTLA-4, and sBTLA Are Promising Markers in Diagnostic and Therapeutic Approaches for Aseptic Loosening and Periprosthetic Joint Infection.
    Jubel JM; Randau TM; Becker-Gotot J; Scheidt S; Wimmer MD; Kohlhof H; Burger C; Wirtz DC; Schildberg FA
    Front Immunol; 2021; 12():687065. PubMed ID: 34421900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
    Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
    BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-treatment prediction of early response to chemoradiotherapy by quantitative analysis of baseline staging FDG-PET/CT and MRI in locally advanced cervical cancer.
    Min LA; Ackermans LL; Nowee ME; Griethuysen JJV; Roberti S; Maas M; Vogel WV; Beets-Tan RG; Lambregts DM
    Acta Radiol; 2021 Jul; 62(7):940-948. PubMed ID: 32722967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Outcomes and Sites of Failure in Locally Advanced, Cervical Cancer Patients Treated by Concurrent Chemoradiation with or without Adjuvant Chemotherapy: ACTLACC Trial.
    Tovanabutra C; Asakij T; Rongsriyam K; Tangjitgamol S; Tharavichitkul E; Sukhaboon J; Kridakara LCA; Paengchit K; Khunnarong J; Atjimakul T; Pariyawateekul P; Tanprasert P; Tungkasamit T; Lorvidhaya V
    Asian Pac J Cancer Prev; 2021 Sep; 22(9):2977-2985. PubMed ID: 34582670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.